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Objective: The purpose of this work was to perfonn kidney trans-
plantation under a regimen of immunosuppression that facilitates 
rather than interferes with the recently defined mechanisms of 
allo(;ngraftment and acquired tolerance. 
Summary Background Data: In almost all centers, mUltiple im-
munosuppressive agents are given in large doses after kidney trans-
plantation in an attempt to reduce the incidence of acute rejection to 
near zero. With the elucidation of the mechanisms of alloengraft-
ment and acquired tolerance. it was realized that such heavy pro-
phylactic immunosuppression could systematically subvert the 
clonal exhaustion-deletion that is the seminal mechanism of toler-
ance. In addition. it has been established that the rejection response 
can be made more readily treatable by pretransplant immunosup-
pression. Consequently, we conducted kidney transplantation in 
compliance with 2 therapeutic principles: recipient pretreatment and 
the least possible use of posttransplant immunosuppression. 
Methods: One-hundred fifty unselected renal transplant recipients 
wi th a mean age of 51 ::!: 15 years and multiple risk factors had 
pretreatment with approximately 5 mg/kg of rabbit antithymocyte 
globulin (Thymoglobulin) in the hours before transplantation, under 
cowring bolus doses of prednisone to prevent cytokine reactions. 
Minimal posttransplant immunosuppression was with tacrolimus 
monotherapy to which steroids or other agents were added only for 
the treatment of rejection. At or after 4 months after transplant, 
spaced-dose weaning from tacrolimus monotherapy was begun in 
patients who had exhibited a ~atisfactory course. 
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Results: One-year actuarial patient and graft survival was 97% and 
92%, respectively. Although the incidence of early aCllte rejection 
was 37%, only 7% required prolonged treatment with any agent 
other than tacrolimus. After a follow-up of 6 to 21 months, the mean 
serum creatinine in patients with functioning grafts is 1.8 ::!: 1.0 
mg/dL. Seventy-three percent of the patients met the cnteria for 
spaced weaning. Although rejection episodes occasionally required 
restoration of daily treatment, 94 (630;;» of the 150 patients currently 
receive tacrolimus in spaced doses ranging from every other day to 
once a week. 
Conclusions: With this approach to immunosuppression. it has been 
possible to avoid early posttransplant overimmunosuppressiun and 
thereby to promote the evolution of a degree of partial tolerance 
sufficient to undertake substantial dose reduction. The strategy, 
which is applicable for all organ grafts, constitutes a paradigm shift 
in transplant management at our center. 
(Ann Surg 2003;238: 520-527) V-
The prophylactic postoperative administration of multiple 
I drugs with the objective of completely preventing acute 
rejection is the most widely used treatment of kidney and 
other kinds of organ transplant recipients. With ever more 
potent agents used in combination, rejection rates < 10% 
have been reported in some series, whereas I-year renal graft 
survival has increased to the current level of nearly 90'%. I 
Chronic rejection has become endemic. however, and there 
have been other disappointments. Continuous treatment with 
the more potent new drugs can damage recipient vital organs. 
cause potentially dangerous metabolic effects. and increase 
the risk of infections and malignant tumors that are normally 
kept under control by the immune system. 
The ideal solution would be to make organ recipients 
more tolerant and thereby less immunosuppression depen-
dent. This objective became realistic with the elucidation of 
the donor leukocyte chimerism-associated mechanisl11~ of 
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acquired tolcrance2 4 and the recognition that organ engraft-
ment is a form of organ-induced partial tolerance. With this 
insight. it could be seen that the mechanisms of tolerance 
(clonal exhaustion-deletion and immune ignorance) can be 
subverted by the customary heavy immunosuppression.s It 
also was proposed that this undesired consequence could be 
prevented by observance of2 therapeutic principles: recipient 
pretreatment and the use of minimal posttransplant immuno-
suppression.s We report here the outcomes in 150 patients 
undergoing renal transplantation under such tolerogenic im-
munosuppression. Details of the first 40 cases were recently 
reported. b 
PATIENTS AND METHODS 
The regimen of immunosuppression was submitted to 
the University of Pittsburgh Institutional Review Board, 
which determined it to be within the boundaries of standard 
therapy. The protocol was then remanded to the Presbyterian 
University Hospital Innovative Practices Committee and to 
the Pharmacy & Therapeutics Committee, with approval by 
both. All patients provided standard informed consent. In 
addition. separate informed consent was obtained for studies 
of immune parameters not routinely obtained in our conven-
tional practice. Data integrity as well as safety and efficacy 
monitoring were assured by establishment ofa weekly formal 
review of all cases. 
Between July 2001 and October 2002, 150 adults un-
derwent kidney transplantation under the described treatment 
regimen (Table I). There were 93 (62%) cadaveric and 57 
(38%) live donors. The mean recipient age was 51 ± 15 years 
(range. 19-80). Twenty-five (17%) were African-American, 
15% were undergoing retransplantation, and 17% had a PRA 
over 20%. The mean number ofHLA mismatches was 3.2 ± 
1.7, and in the cadaver cases, it was 3.3 ± 1.8. Although the 
mean donor age overall was 40.3 ± 15.5 years (range, 
0.5-66), the adult cadaveric donors were 43.8 ± 13.1 years. 
TABLE 1. Graft Survival 
n Functioning 
(%) Grafts (%)* 
Living donor 57 EPUD~/oF 55 (96%) 
Cadaver donor 93 (620/.) 82 (88%) 
Bone man'O\v 41 (27%) 33 (80%) 
No bone 
marrow 109 (73%) 104 (95%) 
Non-Ati'ican 
American 125 (83%) 116 (92%) 
African 
American 25 (17%) 21 (84%) 
• At II :+: 5.4 months. 
c 2003 Lippincott Williams & Wilkins 
mgldL Cr 
(SD)* 
1.81 (1.22) 
1.87 (0.85) 
2.06 (1.54) 
1.77 (0.77) 
1.81 (1.04) 
2.02 (0.83) 
Kidney Transplantation and Immunosuppression 
The mean cold ischemia time of the cadaver kidneys was 26.1 
± 6.6 hours. On the first postoperative day, 41 (27%) of the 
recipients received an infusion of donor bone marrow cells. 7 
Pretreatment consisted of 5 mg/kg antithymocyte glob-
ulin (Thymoglobulin; SangStat. Fremont, CA) in the few 
hours or the evening before transplantation, with concomitant 
l-g bolus( es) as prophylactics against a cytokine release 
syndrome. Twice daily oral tacrolimus (Prograf, Flljisawa 
Healthcare, Inc., Deerfield, IL) was started on postopcrative 
day one, with target 12-hour target trough levels of 10 ng/mL. 
By 3.5-4 months in suitable patients, or in somc cases at a 
later time, the twice-daily dose was consolidated to once a 
day. After 1-2 more months, the dose schedule was changed 
to every other day (Fig. 1). After variable intervals (L1suall y at 
least 2 months), the interval was changed to 3 timcs/week. 
and subsequently to 2 times/week. At about 1 year posttrans-
plantation, selected patients who had been on twice a week 
tacrolimus for at least 4 months were put on once-weekly 
tacrolimus. Once spaced weaning was begun, trough levels of 
tacrolimlls became low, and if they were obtained just before 
the next dose, they were undetectable (Fig. 1). Maintenance 
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FIGURE 1. Uncomplicated postoperative course. The patient 
had immediate graft function and experienced no episodes of 
acute rejection. After a clean biopsy obtained at 90 days, 
weaning by stages was commenced to once-weekly doses of 
tacrolimus. Most of the tacrolimus trough levels during wean-
ing were at 24 or 48 hours. 
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steroids were not routinely administered, nor were mycophe-
nolate mofetil or sirolimus. 
Biopsy-proven breakthrough rejections usually were 
treated first with a I-g bolus of intravenous methylpred-
nisolone. Steroid-resistant rejection was treated either with 
muronmonab-CD3 (OKT3) or alemtuzumab (Campath I H, 
ILEX Pharmaceuticals, LP, San Antonio, TX). Maintenance 
steroids or sirolimus were added if necessary. Conversion 
from tacrolimus to sirolimus was used in cases of significant 
nephrotoxicity. This was perfonned most frequently when 
"expanded criteria" kidneys were used, for example, kidneys 
with preexisting disease (arteriosclerosis arteriolosclerosis, 
interstitial fibrosis, or glomerular sclerosis) or when the 
kidneys were from very old donors. 
RESULTS 
Patient Survival 
After a mean follow-up of 11 ::!:: 5.4 months (range, 
6 -21), the I-year actuarial patient survival was 97%. Four 
(2.7'%) patients died: 1 each from intraoperative volume 
overload (an anesthetic error), intraabdominal sepsis caused 
by retained peritoneal dialysis catheter, a late myocardial 
infarction, and inanition after a prolonged colonic infection 
with Clostridium difficile. None of the 4 deaths was an 
African-American. 
Graft Survival and Function 
The I-year actuarial graft survival is 92%. Including 
the 4 lost from patient death, 13 (8.7%) of the transplanted 
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kidneys were lost. Three of the 9 graft losses not associated 
with mortality were from a combination of preexisting donor 
disease and chronic rejection. The other 6 were caus~d by 
cortical necrosis after an intraoperative Shwartzman reac-
tion, 8 renal artery thrombosis during cardiopulmonary bypass 
and coronary artery reconstruction for an early postoperative 
myocardial infarction, a surgical/technical error, the inability 
to arterialize the renal graft because of recipient p~ripheral 
vascular disease, primary graft nonfunction, and thrombosis 
of a set of en bloc kidneys from a 6-month-old cadaveric 
donor. 
Graft survival in the live versus cadaveric, adjunct bone 
marrow, and African-American subgroups is shown in Table 
1. It is noteworthy that African Americans were underrepre-
sented versus all others in the optimal live donor cases: that 
is, 4/25 (16%) versus 531125 (42.4%). In contrast, they were 
ovelTepresented in historically disadvantaged retransplanta-
tions: 5/25 (20%) versus l71125 (13.6%). Finally, 11/28 
(44%) African-Americans had adjunct donor bone malTOW 
infusion versus 301125 (24%) for all others. Although it is too 
early for a definitive multiVariate analysis, ethnicity per se 
mayor may not have been the dominant factor in the poorer 
graft survival and function in both the cadaver kidney and 
adjunct bone marrow subgroups. 
The mean serum creatinine of the 137 surviving kid-
neys is 1.8 ::!:: 1.0 mg/dL. The analysis of subgroups is shown 
in Table 1. The incidence of delayed graft function, defined as 
the requirement for dialysis in the first week after transplan-
tation, was 23%, reflecting the systematic use of "marginal" 
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FIGURE 2. Delayed graft function necessitating postoperative dialysis support for 1 month of 2 cadaver kidneys transplanted from 
the same older donor in July 2001. Management was dictated by biopsies that showed only ischemia reperfusion injury. Although 
1 patient received donor bone marrow, convalescence in the 2 cases was similar. Weaning was delayed well beyond 4 months to 
allow completion of the slow decline of serum creatinine concentration before altering therapy. Both patients ultimately were 
weaned to twice-weekly doses of tacrolimus. Note that the individual tacrolimus doses after spaced weaning were the same as 
those before. 
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FIGURE 3. A single episode of early acute rejection was treated 
with a single bolus of steroids. Every-other-day spaced wean-
ing was begun at 5 months. The patient now receives 3 
doses/week of tacrolimus. 
cadaver donor kidneys. Management of these cases was not 
different than for the other patients except for greater depen-
dence on early posttransplant biopsies (Fig. 2). 
Incidence of Preweaning Acute Rejection 
Prior to weaning, the incidence of clinical acute rejection, 
diagnosed by biopsy and given a Banff score of lA or highe~ in 
Weaning 
at II +/- 5.5 Mouth. 
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FIGURE 5. Late rejection in a 73-year-old cadaver kidney 
recipient after reduction of the frequency of tacrolimus doses 
from 3 times/week to twice weekly. Two steroid boluses (1 g 
and 0.5 g) and resumption of daily tacrolimus restored base-
line kidney function. Tacrolimus doses were subsequently 
weaned to every other day and are now being given 3 times/ 
week. 
the context of a rising serum creatinine, was 37% (55 of ISO), 
However, most of these rejections were readily reversed with a 
. single 1 g bolus of prednisone (Fig. 3). The incidence of steroid 
resistant rejection was only 7.3% (1 i of 150). 
Spaced Weaning 
Weaning was precluded in 20 cases, in 4 because of 
patient death and in 5 more because of early graft failure (Fig. 
4). Other exclusionary factors were discontinuance oftacroli-
mus because oftoxicity (n = 6), transplantation of a pancreas 
after kidney (n = 3), or transfer of 2 recipients to other cities 
where care givers instituted multiple drugs. A decislOll 
against weaning was made in 8 more cases because of an 
unstable course (Fig. 4). Finally, weaning has not been 
instituted in 9 recipients because of hesitation of patients in 
taking this step or because of procrastination by ollr manage-
ment team. 
Spaced weaning was begun in 113 of the 150 reCIpi-
ents. Twenty-six (23%) of the 113 weaned patients experi-
enced clinical acute rejection at some point subsequent to the 
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institution of weaning. Treatment ranged from a bolus of 
steroids and/or a temporary increase to once daily dosing of 
tacrolimus, to antibody therapy with muromonab-CD3 
(OKT3) or alemtuzumab (Campath IH). Subsequent reinsti-
tution of spaced weaning was often possible (Fig. 5). At 
present, 94 (63%) of the original I SO patients (70% of the 137 
with functioning kidneys) are on every other day (n = 35), 3 
times a week (n = 29), twice a week (n = 19), or once-
weekly (n = It) tacrolimus. 
Nonrenal Morbidity 
Posttransplant diabetes mellitus was observed in 1 
(0.7'%) patient who had sirolimus and prednisone added to 
once daily tacrolimus for a late rejection. The patient was 
able to discontinue insulin after the sirolimus and prednisone 
were stopped, and reinstitution of tacrolimus weaning to 
every other day. Posttransplant lymphoproliferative disorder 
(PTLD) was not observed. Cytomegalovirus was seen in 3 
EOD~{F recipients. who were treated successfully with oral 
valgancyclovir and tacrolimus dosage reduction. One (0.7%) 
patient developed evidence of BK (polyoma) virus. He had 
been on a 3 times/week dose schedule for tacrolimus and was 
treated by reducing tacrolimus to I dose/week and intrave-
nous cidofovir. 
DISCUSSION 
The strategy of immunosuppression described here was 
used in a consecutive and unselected series of kidney trans-
plantations in which there were multiple risk factors: the 
systematic use of "expanded criteria" cadaveric kidneys, 
many older age recipients, a high incidence of retransplanta-
tion and/or presensitization, long cold ischemia times, and 
generally poor HLA matches. Nevertheless, good I-year 
patient (97%) and graft (92%) survival rates were obtained. 
Nearly two thirds of the patients could be weaned to ex-
tremely low levels of maintenance immunosuppression. Con-
sequently, the overall freedom from the morbidity of chronic 
immune depression per se and from the organ-specific toxic-
ity of the individual drugs was striking. Although weaning 
resulted in a 23% incidence of acute rejection, these were 
readily controlled, often with the subsequent resumption of 
weaning. There was very little immediate or subsequent 
morbidity. 
Our experience suggests that the quality of outcome 
with kidney transplantation can be substantially improved by 
simplifying immunosuppression and above all by modifying 
its timing and intensity. However, a drastic change in the 
intellectual culture of transplantation will be required. Until 
now, the development of immunosuppression protocols has 
been driven by the conviction that complete prevention of 
acute rejection is a genuine measure of therapeutic efficacy. 
Contrary to (his belief, rejection and tolerance in the concept 
from which our treatment algorithm derived4 .5 are simply 
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alternative outcomes of the immune activation that is induced 
by the migration of donor passenger leukocytes to recipient 
lymphoid organs. 
In this view, the seminal mechanism of allocngraftmcllt 
and of acquired tolerance is donor leukocyte-driven exhaus-
tion and deletion of the antidonor immune response'" 5 The 
purpose of pretreatment is to reduce global immune respoll-
siveness in advance far enough so the antidonor response 
induced by the graft's passenger leukocytes is brought into a 
more deletable range. The objective of minimal posttrans-
plant immunosuppression is avoidance of depression of the 
donor specific immune activation to such an extent that the 
activation-dependent event of clonal exhaustion-deletion is 
eroded or precluded. 
Of historical interest, a strategy incorporating both the 
principle of recipient pretreatment and the principle of mini-
malistic immunosuppression was used in 1962-1963 at the 
University of Colorado lo for the generation of a bellwether 
series of long-surviving kidney allograft recipients that es-
tablished renal transplantation as a clinical service. I I The 
recipients of kidneys from"46 live related donors were pre-
treated with azathioprine for 1-2 weeks before transplanta-
tion and then given azathioprine monotherapy afterward. 
Prednisone was added only for the indication of overt rejec-
tion. Nine ofthe kidneys subsequently functioned for the next 
4 decades, and are the longest surviving organ allografts in 
the world. 12 Importantly, 7 of the 9 patients became drug-free 
tolerant for periods of 3-38 years. 13 
No similar cluster of tolerant kidney recipients was 
produced subsequently, anywhere in the world. With delin-
eation of the mechanisms of organ engrattment and acquired 
tolerance, the explanation for the failure to duplicate these 
results was evident. In December 1963, pretreatment was 
de-emphasized because a significant number of immunosup-
pression-related infectious complications had OCCUlTed prior 
to transplantation. A second modification was prompted by 
losses of kidney allografts whose: rejections could not be 
reversed or controlled once they had begun. In a violation of 
the principle of minimal posttransplant immunosuppression, 
high doses of prednisone were now instituted from the time of 
operation, rather than as specifically indicated (see * with 
Reference 11). 
The policy of prophylactic high dose early immunosup-
pression with multiple agents (inappropriately called "induc-
tion") has dominated the practice of transplantation iCver since 
with a few exceptions that have been summarized else-
where. 13 In the most recent exception, CaIne et al 14 treated 
cadaver kidney recipients with a few perioperative doses of 
the broadly-reacting humanized monoclonal antibody, ale-
mtuzumab, followed by low daily maintenance doses of 
cyclosporine monotherapy. The authors characterized the 
trouble-free convalescence of their patients by the (el"ln 
"prope tolerance." We believe that CaIne's results reflected 
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the efficient production of genuine partial tolerance. More 
recently. Swanson et al 15 and Knechtle et al 16 have demon-
strated the feasibility of kidney transplantation under siroli-
mus monotherapy in patients pretreated for a week with large 
doses of thymoglobulin or with alemtuzumab (Campath 1 H) 
given intraoperatively and on postoperative day 1. 
The archival and more recent observations with differ-
ent immunosuppressants, as well as our own current experi-
ence reported here and elsewhere,6 suggest that the therapeu-
tic principles of our protocol are neither drug-specific nor 
organ allograft-specific. We began with the use of Thymo-
globulin for pretreatment because it is a well-standardized 
and broadly reacti ve polyclonal antilymphocyte globulin with 
a long rccord of use in transplantation. The monoclonal 
antibody alemtuzumab has similar qualities and has been 
used electively in many of our recent cases. For posttrans-
plant monotherapy, the calcineurin inhibitor, taerolimus. is a 
superior agent. but weaning from cyciospOline and sirolimus 
also was possible in some of our cases. 
Although none of our patients have had total discon-
tinuance of immunosuppression, the development of donor 
specific tolerance is implicit in the ability to wean the ma-
jority of rccipients to every other day, 3 times a week, twice 
a week. or even once per week dose schedules. Moreover, the 
evolution of high. if not absolute, levels of tolerance has been 
formally demonstrated with limiting dilution, mixed lympho-
cyte reactivity, and cytokine assays in some of the first 
patients treated with the current protocol as has been reported 
elsewhere.6 
Much longer follow-up ofthis protocol wiII be required 
to determine whether the high incidence of acute rejection is 
deleterious to long-term graft function and survival. How-
ever, the observations to date appear to presage a new era of 
transplantation in which recipients can aspire to a better 
quality of posttransplant life. Unlike previous improvements 
in care, this one will not be primarily dependent on the 
development of more powerful immunosuppressive agents. 
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Discussion 
DR. JOHN S. NAJARIAN (Minneapolis, Minnesota): Thank 
you, Dr. Shapiro, for an excellent presentation of a consid-
erable amount of data from the Pittsburgh group - as usual, 
very well presented. I also enjoyed reading the corresponding 
paper, which I just received before your presentation. 
I wouJdjust like to make an initial comment. Dr. Matas 
at our institution has concluded a clinical trial of a steroid-
free immunosuppressive protocol for 300 kidney transplant 
recipients with a 3-year follow-up. The steroids were rapidly 
decreased; by postoperative day 6, recipients were no longer 
on them. Under this protocol, the total rejection rate was 6'10; 
only 1 % of those episodes were steroid resistant. In contrast, 
most immunosuppressive protocols today result in acute re-
jection rates of close to 12%. 
Under your 'tolerogenic regimen,' you reported an 
initial 37% acute rejection rate. Then after weaning your 
recipients off of immunosuppression. another 23% of them 
expel;enced acute rejection. Both these numbers seem to be 
very high. A decade ago, we showed that it takes 3 to 5 years 
before it is possible to determine how many kidney recipients 
with acute rejection will go on to chronic rejection. So. your 
conclusion regarding the early nature of your study is very 
important. Until you get late results, it will be difficult to 
understand the meaning of your study. It is an interesting 
concept. though, to get down to monotherapy. All of us will 
be intrigued to hear the late results of your study. I was 
perplexed by the title of your presentation, which used the 
word 'tolerogenic.' But since none of your recipients became 
tolerant. I am wondering what you actually meant by 'tolero-
genic' in the title. It caught my eye as I read the abstract in the 
program booklet. 
Another interesting aspect of your paper is that many 
different investigational strategies were used for these recip-
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ients. There was no single protocol. Some recipients received 
cadaver kidneys; others, living donor kidneys. Some received 
antibody pretransplant; others, Campath; and still others, 
donor bone maITOw. You said that all recipients did about the 
same, but I would be curious to know whether the bone 
marrow recipients, when looked at individually, did any 
better than the nonbone maITOW recipients. 
Another question concerns primary transplant recipi-
ents who were nonsensitized: were their results any different 
from the results of retransplant recipients who were sensi-
tized? Also, did you keep the same dose of tacrolimus all the 
way through, even though you sometimes reduced it to twice 
or even once a week (maintaining it at 1 microgram per liter)? 
Or did you just let the patients continue on the same dose? 
Finally, this could prove to be an important study and I 
certainly look forward to your long-term results. But again, I 
am concerned about the excessively high acute rejection rate 
that you have repOtied. As you know, it is important to see 
whether or not such recipients are eventually going to be 
subjected to chronic rejection; if so, 37% initially and 23% 
after weaning are unacceptable levels of acute rejection. 
Thank you. 
DR. RON SHAPIRO (Pittsburgh, Pennsylvania): Thank 
you, Dr. Najarian. These are all excellent points. 
The rejection incidence reflects a philosophic belief that 
you do need to have some sort of donor and recipient 
interaction. It is thought that if you can keep this under some 
control that you can then get on with subsequent weaning. As 
I showed in the slide with the patient that did have a little bit 
of rejection. it was very easily controlled with a single bolus 
of steroids. and then we were able to continue to wean him. 
Parenthetically, in some of our more recent cases we 
have been using Campath IH 30 mg as preconditioning, 
usually because we do not have the time to give the full dose 
of Thymoglobulin, and the incidence of rejection in that 
series seems to be incredibly low, less than 5%. One of the 
questions, in fact, will be whether it will be too low and we 
will find that we will not be able to wean patients. I will let 
you know as we get more follow-up on these patients. 
I agree with you that these are not formally tolerant 
patients. On the other hand, the doses of immunosuppression 
that they are receiving bear no relationship to anything I 
would have ever predicted 2 years ago, with many patients 
taking once a week or twice a week immunosuppression. 
It is a relatively homogeneous protocol in that patients 
do get preconditioning with 5 mglkl of Thymoglobulin and 
received tacrolimus monotherapy aiming for levels of about 
10. Weaning then tends to follow at reasonably regular 
intervals, beginning at about 4 months. with some variations. 
The subgroup analyses are still a little bit too early to 
perform, as the numbers are quite small, and I cannot really 
comment in terms of actuarial survivals. But when we did a 
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first-pass look at some of these issues, we did not sec any 
significant differences. The bone marrow patients did not do 
better or worse statistically than the patients who did not 
receive bone marrow. In fact, for cadaveric cases now, while 
we are going to continue to follow the patients who received 
donor specific bone marrow, we are not adding new cases at 
the present time. Again, while we do not have sufficient 
follow-up on the patients undergoing retransplantation, it 
does not appear as though there were significant differences 
in outcomes. 
The dosing aims for levels of about 10 mg/ml at the 
beginning for the first 3 or 4 months. Once \\le go to 
once-a-day immunosuppression, we consolidate the twice-a-
day dose to once a day. So someone who is taking 4 mg twice 
a day will go to 8 mg once a day. We will then use the 8 mg 
dosing as we wean, going to every other day, 3 times a week. 
twice a week, and of course at that point the levels become 
essentially undetectable. 
DR. JAMES A. SCHULAK (Cleveland, Ohio): I, too, share 
many of the concerns that Dr. Najarian voiced about this 
paper, particularly the high incidence of rejection. 
I think we all know that early rejection episodes often 
are predictive of the development of chronic rejection and 
poor long-term outcomes. I encourage you to watch these 
patients very carefully to see if that is happening and inter-
vene if it appears to be occurring. 
The hypothesis that you are testing is that the immune 
system after receiving an allograft is a pendulum that can 
swing either in favor of rejection or toward tolerance. You 
also suggest that your potent lymphocyte depleting regimen 
followed by low dose immunosuppression with tacrolimus 
favors the latter. Did you do any type of immune function 
monitoring in these patients afterward that indeed suggests 
that something of this nature is occurring? I think it is very 
important for you to do so if you are going to make the 
statement that this regimen does cause tolerance to occur. 
I think that the analysis of all of your patients as 1 big 
group needs to be addressed. You lump live donor with 
deceased donor transplants as well as patients of all erh-
nicities and both genders. I think it is extremely important 
that you do cohort analysis if we are going to learn more 
about this phenomenon, and I am wondering if you have done 
that. 
Finally, my last question is, do you really think the high 
dose antithymoglobulin is necessary? Might we all achieve 
the same types of results using any of the protocols we 
currently use in our centers if we just try? 
DR. RON SHAPfRO (Pittsburgh, Pennsylvania): Thank 
you, Dr. Schulak. 
Again. the incidence of rejection I have addressed. It 
looks as though by using Campath IH preconditioning we 
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may see much less rejection, although most of the early 
rejections under Thymoglobulin tend to respond to relatively 
little modification of immunosuppression. 
We are we are doing active immune monitoring. We do 
not have the outcomes on that yet. 
The subgroup analysis is in fact important. We have 
tried to take a first look at it. We have not seen anything that 
has been particularly remarkable looking either at living 
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donor versus cadaver outcomes, African-Americans versus 
non-African-Americans, or bone malTow versus non bone 
malTow. However, we need more patients and more fol-
low-up to provide that level of detail. 
I think that you probably do need some sort of precon-
ditioning to be able to wean to such incredibly low doses of 
immunosuppression. I believe that on theoretical grounds you 
need to do that. 
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